Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (noting the metadata reference to Clearpoint Neuro, Inc. appears to be a discrepancy as the filing explicitly names MRI Interventions, Inc.) on December 15, 2015. The report details the entry into a Material Definitive Agreement for a private placement financing transaction.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of 16,309,270 Units.
- Purchase Price: $0.3246 per Unit.
- Gross Proceeds: Approximately $5.3 million.
- Unit Composition: Each Unit consists of one share of common stock, one Series A Warrant (0.40 share), and one Series B Warrant (0.30 share).
- Warrant Terms:
- Series A Warrants: Exercise price of $0.4058 per share; 5-year term.
- Series B Warrants: Exercise price of $0.5275 per share; 5-year term.
- Placement Agent Warrants: Terms similar to Series A; exercisable until May 18, 2023.
- Placement Agent: Brookline Group, LLC (lead agent), earning cash commissions and warrants.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement with accredited investors. The transaction is subject to customary closing conditions, with an anticipated closing date on or before December 18, 2015. The Company may enter into additional agreements for further closings.
In connection with the closing, the Company will enter into a Registration Rights Agreement requiring the filing of a registration statement with the SEC within 30 calendar days of closing to cover the resale of shares issued to investors and shares underlying the warrants.
Guidance, Risks, and Contingencies
- Closing Contingency: There is no assurance the Financing Transaction will be completed on the described terms or in a timely manner.
- Liquidated Damages: The Company will incur liquidated damages if the Registration Statement is not filed by the deadline, not declared effective within 75 days (or 120 days if reviewed by the SEC), or if effectiveness is not maintained.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the closing and proceeds, which are subject to market conditions and other uncertainties.
- Regulatory Compliance: The sale relies on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $5.3 million gross proceeds.
- Confirm the filing and effectiveness of the Registration Statement within the required 30-day and 75-day windows to avoid liquidated damages.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant forms (Exhibits 4.1 and 4.2) for specific adjustment provisions and cashless exercise terms.
- Assess the dilution impact of the 16.3 million new shares plus the potential issuance of shares from the Series A and Series B warrants.
- Check for any subsequent filings regarding additional closings or changes to the financing terms.